Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.89 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -1.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.88 | |||||
| Beneish M-Score | 2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1598 | |||||
| 3-Year EBITDA Growth Rate | 9.5 | |||||
| 3-Year EPS without NRI Growth Rate | 15.7 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | 41 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.79 | |||||
| 9-Day RSI | 19.26 | |||||
| 14-Day RSI | 10.2 | |||||
| 6-1 Month Momentum % | -40 | |||||
| 12-1 Month Momentum % | -40 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.89 | |||||
| Quick Ratio | 5.89 | |||||
| Cash Ratio | 5.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -15.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -46.73 | |||||
| Net Margin % | -35.09 | |||||
| FCF Margin % | -50.56 | |||||
| ROE % | -16.29 | |||||
| ROA % | -9.78 | |||||
| ROIC % | -41.35 | |||||
| ROC (Joel Greenblatt) % | -74.04 | |||||
| ROCE % | -15.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.57 | |||||
| PB Ratio | 1.8 | |||||
| Price-to-Tangible-Book | 1.8 | |||||
| EV-to-EBIT | -4.23 | |||||
| EV-to-Forward-EBIT | -3.65 | |||||
| EV-to-EBITDA | -4.77 | |||||
| EV-to-Forward-EBITDA | -4.09 | |||||
| EV-to-Revenue | 1.97 | |||||
| EV-to-Forward-Revenue | 37.41 | |||||
| EV-to-FCF | -4.16 | |||||
| Price-to-Net-Current-Asset-Value | 2.41 | |||||
| Price-to-Net-Cash | 2.48 | |||||
| Earnings Yield (Greenblatt) % | -23.62 | |||||
| FCF Yield % | -10.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 6,525.728 | ||
| EPS (TTM) (MXN) | -34.449 | ||
| Beta | 0 | ||
| Volatility % | 40 | ||
| 14-Day RSI | 10.2 | ||
| 14-Day ATR (MXN) | 0.070741 | ||
| 20-Day SMA (MXN) | 450 | ||
| 12-1 Month Momentum % | -40 | ||
| 52-Week Range (MXN) | 440 - 750 | ||
| Shares Outstanding (Mil) | 82.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beam Therapeutics Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(MEX:BEAM)'s stock price today?
The current price of MEX:BEAM is MXN450.00. The 52 week high of MEX:BEAM is MXN750.00 and 52 week low is MXN440.00.
When is next earnings date of Beam Therapeutics Inc(MEX:BEAM)?
The next earnings date of Beam Therapeutics Inc(MEX:BEAM) is 2024-05-10 Est..
Does Beam Therapeutics Inc(MEX:BEAM) pay dividends? If so, how much?
Beam Therapeutics Inc(MEX:BEAM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers